<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="thctd" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">thctd</book-part-id>
      <title-group>
        <title>MCT8-Specific Thyroid Hormone Cell-Membrane Transporter Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonym: Allan-Herndon-Dudley Syndrome</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dumitrescu</surname>
            <given-names>Alexandra M</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>alexd@uchicago.edu</email>
          <aff>Assistant Professor, University of Chicago Medical Center<break/>Chicago, Illinois</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fu</surname>
            <given-names>Jiao</given-names>
          </name>
          <degrees>MD</degrees>
          <email>fujiaoxyz@uchicago.edu</email>
          <aff>Visiting Graduate Student, University of Chicago Medical Center<break/>Chicago, Illinois</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dempsey</surname>
            <given-names>Melissa A</given-names>
          </name>
          <degrees>MS</degrees>
          <email>meldempsey23@gmail.com</email>
          <aff>Certified Genetic Counselor, Parkview Health<break/>Fort Wayne, Indiana</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Refetoff</surname>
            <given-names>Samuel</given-names>
          </name>
          <degrees>MD</degrees>
          <email>refetoff@uchicago.edu</email>
          <aff>Professor of Medicine, Pediatrics &#x00026; Genetics<break/>University of Chicago Medical Center<break/>Chicago, Illinois</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2010-03-09" date-type="created">
          <day>9</day>
          <month>3</month>
          <year>2010</year>
        </date>
        <date iso-8601-date="2013-04-11" date-type="updated">
          <day>11</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="mbd5-dis" document-type="chapter">
<italic toggle="yes">MBD5</italic> Haploinsufficiency</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="mecp2-dup" document-type="chapter"><italic toggle="yes">MECP2</italic> Duplication Syndrome</related-object>
      <abstract id="thctd.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency is characterized by severe cognitive deficiency, infantile hypotonia, diminished muscle mass and generalized muscle weakness, progressive spastic quadriplegia, joint contractures, and dystonic and/or athetoid movement with characteristic paroxysms or kinesigenic dyskinesias. Seizures occur in about 25% of cases. Most affected males never sit or walk independently or lose these abilities over time; most never speak or have severely dysarthric speech. Brain MRI obtained in the first few years of life shows transient delayed myelination, which improves by age four years. Although psychomotor findings observed in affected males do not occur in heterozygous females, the latter often have thyroid test abnormalities intermediate between affected and normal individuals.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>All affected males tested to date have had pathognomonic thyroid test results including high serum 3,3&#x02019;,5-triiodothyronine (T<sub>3</sub> ) concentration and low serum 3,3&#x02019;,5&#x02019;-triiodothyronine (reverse T<sub>3</sub> or rT<sub>3</sub>) concentration. Serum tetraiodothyronine (thyroxine or T<sub>4</sub>) concentration is often reduced, but may be within the low normal range; serum TSH concentrations are normal or slightly elevated. <italic toggle="yes">SLC16A2</italic> (also known as <italic toggle="yes">MCT8</italic>) is the only gene in which pathogenic variants are known to cause this disorder.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Physical, occupational, and speech therapies, if necessary. Anticholinergics, L-DOPA, carbamazepine, or lioresol for the treatment of dystonia. Glycopyrolate or scopolamine to reduce drooling. Standard antiepileptic drugs to control seizures, if present. Placement of permanent feeding tube to maintain caloric intake.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Braces to prevent joint contractures and orthopedic surgery, if necessary. Dietary restrictions to prevent aspiration.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular orthopedic evaluations to monitor scoliosis or joint problems; ongoing developmental assessments.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Administration of L-T<sub>4</sub> or L-T<sub>3</sub> alone can exacerbate the high serum T<sub>3</sub> levels and the resulting hypermetabolism.</p>
          <p><italic toggle="yes">Other</italic>: Thyroid hormone treatment, in replacement doses, during childhood has no beneficial effect. Combined treatment with high doses of levothyroxine (L-T<sub>4</sub>) and propylthiouracil (PTU), which inhibits deiodinase 1, has been shown to ameliorate the hypermetabolic state, with beneficial effects on body weight and heart rate. Similarly a thyromimetic compound diiodothyropropionic acid (DITPA) given to four affected children improved the hypermetabolic state. However, both therapies resulted in no significant neurologic improvement.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency is inherited in an X-linked manner. Women who are carriers have a 50% chance of transmitting the <italic toggle="yes">SLC16A2</italic> pathogenic variant in each pregnancy. Male offspring who inherit the pathogenic variant will be affected; female offspring who inherit the variant will be carriers and will usually not be affected although they may have minor thyroid test abnormalities. No affected male has reproduced. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant in the family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="thctd.Diagnosis">
        <title>Diagnosis</title>
        <sec id="thctd.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The features described in 100% of individuals with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency are hypotonia and severe intellectual disability. Thus, the diagnosis should be suspected in males with at least two of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hypotonia/dystonia and feeding difficulties in the first months of life</p>
            </list-item>
            <list-item>
              <p>Truncal hypotonia</p>
            </list-item>
            <list-item>
              <p>Muscle hypoplasia/asthenic build</p>
            </list-item>
            <list-item>
              <p>Poor head control</p>
            </list-item>
            <list-item>
              <p>Spastic paraparesis with dystonic/athetoic movements (with extensor posturing mainly affecting the distal upper limbs)</p>
            </list-item>
            <list-item>
              <p>Paroxysmal dyskinesia</p>
            </list-item>
            <list-item>
              <p>Dysarthric or no speech</p>
            </list-item>
            <list-item>
              <p>Severe psychomotor retardation and cognitive impairment</p>
            </list-item>
          </list>
          <p>Other findings include poor weight gain, limb rigidity with contractures, brisk deep tendon reflexes, clonus, and seizures.</p>
          <p>Brain MRI shows absent or markedly delayed myelination that may not be appreciated after age four years [<xref ref-type="bibr" rid="thctd.REF.holden.2005.852">Holden et al 2005</xref>, <xref ref-type="bibr" rid="thctd.REF.kakinuma.2005.552">Kakinuma et al 2005</xref>, <xref ref-type="bibr" rid="thctd.REF.sijens.2008.1854">Sijens et al 2008</xref>, <xref ref-type="bibr" rid="thctd.REF.gika.2010.475">Gika et al 2010</xref>, <xref ref-type="bibr" rid="thctd.REF.tsurusaki.2011.606">Tsurusaki et al 2011</xref>, <xref ref-type="bibr" rid="thctd.REF.tonduti.2013.795">Tonduti et al 2013</xref>]. Note: Early reports of normal MRI in this disorder were from older individuals.</p>
        </sec>
        <sec id="thctd.Testing">
          <title>Testing</title>
          <p><bold>Affected males</bold>. See <xref ref-type="fig" rid="thctd.F1">Figure 1</xref>. Males with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency have pathognomonic thyroid test results including the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>High serum 3,3&#x02019;,5-triiodothyronine (T<sub>3</sub> ) concentration and low serum 3,3&#x02019;,5&#x02019;-triiodothyronine (reverse T<sub>3</sub> or rT<sub>3</sub>) concentration Note: All individuals with <italic toggle="yes">SLC16A2</italic> pathogenic variants had high serum T<sub>3</sub> concentration and, when obtained, low serum rT<sub>3</sub> concentration. This holds true for both total and free hormone concentrations in serum.</p>
            </list-item>
            <list-item>
              <p>Serum tetraiodothyronine (thyroxine or T<sub>4</sub>) concentration that is often reduced, but may be within the low normal range</p>
            </list-item>
            <list-item>
              <p>Serum TSH concentrations that are normal or slightly elevated (<xref ref-type="fig" rid="thctd.F1">Figure 1</xref>) [<xref ref-type="bibr" rid="thctd.REF.refetoff.2007.277">Refetoff &#x00026; Dumitrescu 2007</xref>, <xref ref-type="bibr" rid="thctd.REF.dumitrescu.2009">Dumitrescu &#x00026; Refetoff 2009</xref>]</p>
            </list-item>
          </list>
          <p><bold>Carrier females</bold>. Thyroid hormone concentrations in female carriers are intermediate between affected males and unaffected family members (<xref ref-type="fig" rid="thctd.F1">Figure 1</xref>) [<xref ref-type="bibr" rid="thctd.REF.refetoff.2007.277">Refetoff &#x00026; Dumitrescu 2007</xref>, <xref ref-type="bibr" rid="thctd.REF.dumitrescu.2009">Dumitrescu &#x00026; Refetoff 2009</xref>]. However, results of thyroid tests in females cannot be reliably used to identify carrier females; carrier status determination requires molecular genetic testing.</p>
          <sec id="thctd.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">SLC16A2</italic> is the only gene in which pathogenic variants are known to cause MCT8-specific thyroid hormone cell-membrane transporter deficiency.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="thctd.T.summary_of_molecular_genetic_tes" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in MCT8-Specific Thyroid Hormone Cell-Membrane Transporter Deficiency</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_2">Test Method</th>
                    <th id="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_3">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4" id="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Affected Males</th>
                    <th headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4" id="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Carrier Females&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">SLC16A2</italic>
                    </td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis</td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4 hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4 hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon or whole-gene deletion</td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4 hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_1_4 hd_h_thctd.T.summary_of_molecular_genetic_tes_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="thctd.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="thctd" object-id="thctd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="thctd.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="thctd.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="thctd.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="thctd.TF.1.4">
                  <label>4. </label>
                  <p>When no affected males in the family are available for testing</p>
                </fn>
                <fn id="thctd.TF.1.5">
                  <label>5. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="thctd.TF.1.6">
                  <label>6. </label>
                  <p>Sequence analysis of <italic toggle="yes">SLC16A2</italic> is expected to identify a pathogenic variant in most affected individuals with the typical thyroid test results; however, the exact variant detection rate is unknown.</p>
                </fn>
                <fn id="thctd.TF.1.7">
                  <label>7. </label>
                  <p>Sequence analysis of genomic DNA cannot detect deletion of one or more exons or the entire X-linked gene in a heterozygous female.</p>
                </fn>
                <fn id="thctd.TF.1.8">
                  <label>8. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="thctd.TF.1.9">
                  <label>9. </label>
                  <p>Exon and multiexon deletions have been reported but the frequency is unknown [<xref ref-type="bibr" rid="thctd.REF.vaursbarri_re.2009.114">Vaurs-Barri&#x000e8;re et al 2009</xref>, <xref ref-type="bibr" rid="thctd.REF.visser.2009.29">Visser et al 2009</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="thctd.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The diagnosis of MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency can be established in a male with psychomotor delays and the characteristic thyroid test results.</p>
          <list list-type="bullet">
            <list-item>
              <p>To date, no persons with <italic toggle="yes">SLC16A2</italic> pathogenic variants have been reported with normal or non-characteristic thyroid test results; thus, it is recommended that thyroid testing (including T<sub>3</sub> and rT<sub>3</sub> concentrations) be performed first.</p>
            </list-item>
            <list-item>
              <p>The diagnosis is confirmed when a pathogenic variant or deletion is identified in <italic toggle="yes">SLC16A2</italic> through sequence analysis or deletion/duplication analysis, respectively.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk female relatives</bold> can be done either (a) after prior identification of the pathogenic variant in the family or, (b) if an affected male is not available for thyroid hormone testing, by sequence analysis. If no pathogenic variant is identified, other methods to detect deletion/duplication abnormalities can be used.</p>
          <p>Note: Carrier females are heterozygous for this X-linked disorder and usually do not develop clinical findings related to the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="thctd.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="thctd.Clincal_Description">
          <title>Clincal Description</title>
          <p><bold>Neonatal period.</bold> Infants with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency have normal length, weight, and head circumference measurements at birth. Hypotonia and feeding difficulties can appear in the first weeks or months of life.</p>
          <p><bold>Growth.</bold> Linear growth is typically normal, but approximately 20% of males have short stature [<xref ref-type="bibr" rid="thctd.REF.schwartz.2007.307">Schwartz &#x00026; Stevenson 2007</xref>]. Weight gain lags behind linear growth; microcephaly becomes apparent with advancing age.</p>
          <p><bold>Craniofacial.</bold> Common facial findings that may be attributed to prenatal and infantile hypotonia include ptosis, open mouth, and a tented upper lip. Ear length is above the 97<sup>th</sup> centile in about half of adults. Cup-shaped ears, thickening of the nose and ears, upturned earlobes, and a decrease in facial creases are also reported.</p>
          <p><bold>Neuromuscular.</bold> Truncal hypotonia persists into adulthood. Progressive hypertonicity of the limbs leads to spastic quadriplegia and joint contractures. Overall, muscle mass is diminished and associated with generalized muscle weakness. Affected males are described with &#x0201c;limber neck&#x0201d; or poor head control even as adults.</p>
          <p>It is common for affected males to experience purposeless movements described as dystonic and/or athetoid and characteristic paroxysms or kinesigenic dyskinesias [<xref ref-type="bibr" rid="thctd.REF.brockmann.2005.663">Brockmann et al 2005</xref>, <xref ref-type="bibr" rid="thctd.REF.fuchs.2009.240">Fuchs et al 2009</xref>]. These can be triggered by somatosensory stimuli, including changing clothes or lifting the affected child. During attacks, the body extends and the mouth opens; stretching or flexing of the limbs lasts as long as one to two minutes.</p>
          <p>Seizures occur in approximately 25% of individuals with onset during infancy or early childhood [<xref ref-type="bibr" rid="thctd.REF.schwartz.2007.307">Schwartz &#x00026; Stevenson 2007</xref>].</p>
          <p>Brisk reflexes, ankle clonus, and extensor plantar responses (Babinski sign) are common. Rotary nystagmus and disconjugate eye movements have been reported but are not common [<xref ref-type="bibr" rid="thctd.REF.dumitrescu.2004.168">Dumitrescu et al 2004</xref>].</p>
          <p><bold>Skeletal.</bold> Pectus excavatum and scoliosis are common, most likely the result of hypotonia and reduced muscle mass.</p>
          <p><bold>Behavior.</bold> Generally, affected individuals are attentive, friendly, and docile. They are not aggressive or destructive.</p>
          <p><bold>Development.</bold> Psychomotor retardation is observed in 100% of affected males. Most affected males either never sit or walk independently or lose these abilities over time. In addition, most affected males never speak or may develop only garbled sounds secondary to severely dysarthric speech.</p>
          <p><bold>Other</bold>. Findings typical of hypothyroidism in infancy (i.e., prolonged neonatal jaundice, myxedematous skin changes, macroglossia, hoarseness, umbilical hernias, and short stature) are absent [<xref ref-type="bibr" rid="thctd.REF.schwartz.2005.41">Schwartz et al 2005</xref>].</p>
          <p><bold>Life span.</bold> Early death has occurred in some individuals, usually caused by recurrent infections and/or aspiration pneumonia. In a few instances survival beyond age 70 years has been reported.</p>
          <p><bold>Affected heterozygous females.</bold> A female with typical features of MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency with a <italic toggle="yes">de novo</italic> translocation disrupting <italic toggle="yes">SLC16A2</italic> and unfavorable nonrandom X-inactivation was reported [<xref ref-type="bibr" rid="thctd.REF.frints.2008.1029">Frints et al 2008</xref>].</p>
          <p>Although most of the psychomotor findings described above do not occur in heterozygous females, intellectual delay and intellectual disability have in rare instances been reported [<xref ref-type="bibr" rid="thctd.REF.dumitrescu.2004.168">Dumitrescu et al 2004</xref>, <xref ref-type="bibr" rid="thctd.REF.schwartz.2005.41">Schwartz et al 2005</xref>, <xref ref-type="bibr" rid="thctd.REF.herzovich.2007.1">Herzovich et al 2007</xref>]. However, whether a causative relationship exists between <italic toggle="yes">SLC16A2</italic> pathogenic variants and cognitive impairments in heterozygous females has yet to be proven [<xref ref-type="bibr" rid="thctd.REF.schwartz.2005.41">Schwartz et al 2005</xref>].</p>
        </sec>
        <sec id="thctd.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>A few pathogenic missense variants (<xref ref-type="table" rid="thctd.T.slc16a2_allelic_variants_discuss">p.Ser194Phe</xref>, <xref ref-type="table" rid="thctd.T.slc16a2_allelic_variants_discuss">p.Leu434Trp</xref>, <xref ref-type="table" rid="thctd.T.slc16a2_allelic_variants_discuss">p.Leu492Pro</xref>, <xref ref-type="table" rid="thctd.T.slc16a2_allelic_variants_discuss">p.Leu568Pro</xref>) and the deletion of a single amino acid (<xref ref-type="table" rid="thctd.T.slc16a2_allelic_variants_discuss">p.Phe501del</xref>) have been associated with milder psychomotor delays, including some speech development, some reading/writing, and/or the ability to walk without support despite ataxia [<xref ref-type="bibr" rid="thctd.REF.schwartz.2005.41">Schwartz et al 2005</xref>, <xref ref-type="bibr" rid="thctd.REF.jansen.2008.2184">Jansen et al 2008</xref>, <xref ref-type="bibr" rid="thctd.REF.visser.2009.29">Visser et al 2009</xref>, <xref ref-type="bibr" rid="thctd.REF.visser.2013.310">Visser et al 2013</xref>]. Independent walking and speech development are unusual in affected males with other pathogenic variants.</p>
        </sec>
        <sec id="thctd.Penetrance">
          <title>Penetrance</title>
          <p>No unaffected males with <italic toggle="yes">SLC16A2</italic> pathogenic variants have been reported; thus, penetrance appears to be 100%.</p>
          <p>Heterozygous females are typically clinically normal.</p>
        </sec>
        <sec id="thctd.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation has not been observed.</p>
        </sec>
        <sec id="thctd.Nomenclature">
          <title>Nomenclature</title>
          <p>MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency was given as a name of this condition, following the identification of the gene and the defect in thyroid hormone metabolism.</p>
          <p>Because of the overlap between the clinical phenotype in individuals with <italic toggle="yes">SLC16A2</italic> abnormalities and in those with a previously described syndrome, Allan-Herndon-Dudley syndrome (AHDS), <xref ref-type="bibr" rid="thctd.REF.schwartz.2005.41">Schwartz et al [2005]</xref> analyzed <italic toggle="yes">SLC16A2</italic> in six families with AHDS. <italic toggle="yes">SLC16A2</italic> pathogenic variants were identified in all six; therefore, AHDS is now synonymous with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency due to pathogenic variants in <italic toggle="yes">SLC16A2</italic>.</p>
        </sec>
        <sec id="thctd.Prevalence">
          <title>Prevalence</title>
          <p>Prevalence of MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency remains unknown. However, the identification of more than 100 families in approximately ten years suggests that the syndrome is more common than previously expected.</p>
        </sec>
      </sec>
      <sec id="thctd.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><italic toggle="yes">SLC16A2</italic> pathogenic variants have been suspected as a cause of nonsyndromic X-linked intellectual disability (i.e., without thyroid hormone abnormalities); however, one study that examined 401 male sibships with intellectual disability who had had no preliminary thyroid testing found an <italic toggle="yes">SLC16A2</italic> variant in only one family. Subsequent thyroid testing revealed that the affected individuals did have the typical thyroid test results [<xref ref-type="bibr" rid="thctd.REF.frints.2008.1029">Frints et al 2008</xref>].</p>
      </sec>
      <sec id="thctd.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Many disorders demonstrate hypotonia and severe intellectual disability in an X-linked inheritance pattern. Several disorders, described below, also demonstrate spasticity, seizures, or other features that overlap with the neurologic phenotype of the MCT8-specific thyroid hormone cell-membrane transporter deficiency and should be considered.</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="pmd" document-type="chapter">Pelizaeus-Merzbacher disease</related-object> (PMD) and other <italic toggle="yes">PLP1</italic>-related disorders display a wide spectrum of phenotypes but can manifest in infancy or early childhood with nystagmus, hypotonia, and severe cognitive impairment and eventually progress to severe spasticity and ataxia. As with males with <italic toggle="yes">SLC16A2</italic> pathogenic variants, males with PMD present with delayed myelination during early childhood; however, they do not have the thyroid test abnormalities characteristic of MCT8-specific thyroid hormone cell-membrane transporter deficiency. <italic toggle="yes">PLP1</italic>-related disorders are inherited in an X-linked pattern, and 80%-95% of males with a <italic toggle="yes">PLP1</italic>-related disorder have a pathogenic variant in <italic toggle="yes">PLP1</italic>. Of note, in one study <italic toggle="yes">SLC16A2</italic> pathogenic variants were reported in 11% of 53 families with a severe form of Pelizaeus-Merzbacher-like disease with an unusual improvement in myelination with age [<xref ref-type="bibr" rid="thctd.REF.vaursbarri_re.2009.114">Vaurs-Barri&#x000e8;re et al 2009</xref>].</p>
          </list-item>
          <list-item>
            <p>Individuals with leukodystrophies, including <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">metachromatic leukodystrophy</related-object> (arylsulfatase A deficiency), <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="krabbe" document-type="chapter">Krabbe disease</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="canavan" document-type="chapter">Canavan disease</related-object> have hypotonia, muscle wasting, and spasticity with no speech or ambulation. However, MRI, nerve conduction velocity (NCV) and evoked potentials are usually abnormal in these disorders.</p>
          </list-item>
          <list-item>
            <p>Males with <related-object link-type="booklink" source-id="gene" document-id="mecp2-dup" document-type="chapter"><italic toggle="yes">MECP2</italic> duplication syndrome</related-object> have infantile hypotonia, severe intellectual disability, absent speech, progressive spasticity, and seizures. Approximately 75% also have recurrent respiratory infections.</p>
          </list-item>
        </list>
      </sec>
      <sec id="thctd.Management">
        <title>Management</title>
        <p>No current published guidelines exist to establish the extent of disease or proper management in an individual diagnosed with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency. The following recommendations are based on current literature and the authors&#x02019; experience.</p>
        <sec id="thctd.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an affected individual, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Growth parameters</p>
            </list-item>
            <list-item>
              <p>Developmental assessment</p>
            </list-item>
            <list-item>
              <p>Neurologic evaluation and EEG to assess possible seizures</p>
            </list-item>
            <list-item>
              <p>Orthopedic evaluation to assess for possible developing scoliosis or pectus deformities</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="thctd.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The following treatment is appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Physical, occupational, and speech therapies, if necessary</p>
            </list-item>
            <list-item>
              <p>Medications, such as anticholinergics, L-DOPA, carbamazepine, or lioresol, for the treatment of dystonia</p>
            </list-item>
            <list-item>
              <p>Glycopyrolate or scopolamine to improve drooling</p>
            </list-item>
            <list-item>
              <p>Standard anticonvulsant medication to control seizures, if present</p>
            </list-item>
            <list-item>
              <p>Placement of permanent feeding tube to avert malnutrition</p>
            </list-item>
          </list>
          <p>Note: Thyroid hormone treatment with replacement doses during childhood has no beneficial effect. However, combined treatment with high doses of levothyroxine (L-T<sub>4</sub>) and propylthiouracil (PTU), which inhibits deiodinase 1, has been shown to ameliorate the hypermetabolic state, with beneficial effects on body weight and heart rate, as seen in several affected individuals [<xref ref-type="bibr" rid="thctd.REF.w_meau.2008.2084">W&#x000e9;meau et al 2008</xref>, <xref ref-type="bibr" rid="thctd.REF.visser.2013.310">Visser et al 2013</xref>]. See also <xref ref-type="sec" rid="thctd.Therapies_Under_Investigation">Therapies Under Investigation</xref>.</p>
        </sec>
        <sec id="thctd.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>Appropriate measures include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Braces to prevent joint contractures and orthopedic surgery, if necessary</p>
            </list-item>
            <list-item>
              <p>Diet restrictions to prevent aspiration</p>
            </list-item>
          </list>
        </sec>
        <sec id="thctd.Surveillance">
          <title>Surveillance</title>
          <p>Appropriate surveillance includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Regular orthopedic evaluations to monitor scoliosis or joint problems</p>
            </list-item>
            <list-item>
              <p>Ongoing developmental assessments</p>
            </list-item>
          </list>
        </sec>
        <sec id="thctd.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Aspiration of food should be avoided to prevent pneumonia.</p>
          <p>Administration of L-T<sub>4</sub> or L-T<sub>3</sub> alone can exacerbate the high serum T<sub>3</sub> levels and the resulting hypermetabolism.</p>
        </sec>
        <sec id="thctd.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="thctd.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="thctd.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>In a recent report, two unaffected heterozygous pregnant women with unaffected fetuses were treated with L-T<sub>4</sub> in the second half of pregnancy [<xref ref-type="bibr" rid="thctd.REF.ramos.2011.309">Ramos et al 2011</xref>]. It is unclear if this had any effect, either beneficial or detrimental, on the fetus. Of note, many unaffected heterozygous mothers have given birth to normal unaffected children without any prenatal treatment.</p>
        </sec>
        <sec id="thctd.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Diiodothyropropionic acid (DITPA), a thyroid hormone analog that does not require MCT8 for transfer into cells, has been evaluated as a treatment in both a mouse model of Mct8 deficiency and in humans with MCT8-specific thyroid hormone cell-membrane transporter deficiency [<xref ref-type="bibr" rid="thctd.REF.di_cosmo.2009.4450">Di Cosmo et al 2009</xref>, <xref ref-type="bibr" rid="thctd.REF.verge.2012.4515">Verge et al 2012</xref>]. DITPA therapy was given to four affected children with subsequent improvement in the hypermetabolic state; however, no significant neurologic improvement was obtained with this therapy. Consideration is being given to DITPA treatment during pregnancy, however such treatment has not been used to date, and there is no information on whether it will be effective.</p>
          <p>Recently another analog TETRAC (3, 3&#x02019;, 5, 5&#x02019;-tetraiodothyroacetic acid) has been tested in mice with Mct8 deficiency [<xref ref-type="bibr" rid="thctd.REF.horn.2013.968">Horn et al 2013</xref>]. TETRAC treatment was able to promote TH-dependent neuronal differentiation in some brain areas but was ineffective in suppressing TRH (thyrotropin releasing hormone) in the hypothalamus. The efficacy of TETRAC therapy may vary among distinct neuronal populations or among different genes that are controlled by TH in a positive or negative manner. However, peripheral tissue thyrotoxicity in Mct8-deficient mice was not significantly ameliorated by TETRAC therapy.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="thctd.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="thctd.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency is inherited in an X-linked manner.</p>
        </sec>
        <sec id="thctd.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disease nor will he be a carrier of the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is an obligate carrier.</p>
            </list-item>
            <list-item>
              <p>If pedigree analysis reveals that the proband is the only affected family member, the possible genetic explanations are:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The proband has a <italic toggle="yes">de novo</italic> pathogenic variant. In this instance, the proband&#x02019;s mother does not have a pathogenic variant. <italic toggle="yes">De novo</italic> variants have been reported in MCT8-specific thyroid hormone cell-membrane transporter deficiency [Author, personal communication; <xref ref-type="bibr" rid="thctd.REF.dumitrescu.2004.168">Dumitrescu et al 2004</xref>].</p>
                </list-item>
                <list-item>
                  <p>The proband&#x02019;s mother has a <italic toggle="yes">de novo</italic> pathogenic variant. Two types of <italic toggle="yes">de novo</italic> pathogenic variants may be present in the mother: a. A germline variant that was present at the time of her conception, is present in every cell of her body, and is detectable in her leukocytes; ORb. A pathogenic variant that is present only in her ovaries (termed "germline mosaicism") in which some germ cells have the variant and some do not, and in which the variant is not detectable in leukocyte DNA. Germline mosaicism has not been reported in MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency but has been observed in many X-linked disorders and should be considered in the genetic counseling of at-risk family members.In either of the preceding scenarios: all offspring of the proband&#x02019;s mother are at risk of inheriting the pathogenic variant; sibs of the proband&#x02019;s mother are not at risk of inheriting the variant.</p>
                </list-item>
                <list-item>
                  <p>The mother is a carrier and has inherited the pathogenic variant either from her mother, in whom the variant was <italic toggle="yes">de novo</italic>, or from her asymptomatic father, who has germline mosaicism for the variant.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of a proband depends on the genetic status of the parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother of the proband has an <italic toggle="yes">SLC16A2</italic> pathogenic variant, the chance of transmitting the variant in each pregnancy is 50%. Males who inherit the pathgoenic variant will be affected; females who inherit the variant will be carriers and will usually not be affected but may have minor thyroid test abnormalities.</p>
            </list-item>
            <list-item>
              <p>If the family-specific <italic toggle="yes">SLC16A2</italic> sequence abnormality is not detected in the mother, the risk to the sibs of a proband is much reduced, but greater than that of the general population. The risk depends on the probability of germline mosaicism in a parent of the proband and the spontaneous mutation rate of <italic toggle="yes">SLC16A2</italic>. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a male proband.</bold> Affected males do not reproduce.</p>
          <p><bold>Offspring of a female proband.</bold> Affected females may not reproduce; the only affected female reported had hypogonadotropic hypogonadism [<xref ref-type="bibr" rid="thctd.REF.frints.2008.1029">Frints et al 2008</xref>]. Women carrying an <italic toggle="yes">SLC16A2</italic> pathogenic variant have a 50% chance of transmitting the variant to each child: sons who inherit the pathogenic variant will be affected; daughters who inherit the variant will be carriers and may have minor thyroid test abnormalities.</p>
          <p><bold>Other family members of a proband.</bold> If the mother of the proband has a pathogenic variant, her female relatives may be at risk of being carriers (typically asymptomatic, although they may have minor thyroid test abnormalities) and her male relatives may be at risk of being affected depending on their genetic relationship to the proband. Phenotypically normal males are unlikely to carry the pathogenic variant.</p>
        </sec>
        <sec id="thctd.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing of at-risk female relatives is possible if the pathogenic variant has been identified in the family.</p>
        </sec>
        <sec id="thctd.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="thctd.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variant has been identified in the family, prenatal diagnosis for pregnancies at increased risk may be available from a laboratory offering either testing for the gene/disease or custom prenatal testing.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="thctd.Resources">
        <title>Resources</title>
      </sec>
      <sec id="thctd.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="thctd.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Monocarboxylate transporter 8 (MCT8) the protein product of <italic toggle="yes">SLC16A2</italic>, is thought to play a role in neuronal T<sub>3</sub> uptake and in endothelial cells allowing partial entry of thyroid hormone through the blood-brain barrier. MCT8 deficiency results in an insufficient supply of T<sub>3</sub> to nuclear T<sub>3</sub> receptors. Thyroid hormone plays a crucial role in brain development. Thus, it is presumed that the decreased access of T<sub>3</sub> to brain cells can lead to the severe defects in neurologic development seen in males with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency [<xref ref-type="bibr" rid="thctd.REF.friesema.2006.512">Friesema et al 2006</xref>, <xref ref-type="bibr" rid="thctd.REF.roberts.2008.6251">Roberts et al 2008</xref>, <xref ref-type="bibr" rid="thctd.REF.ceballos.2009.2491">Ceballos et al 2009</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC16A2</italic> consists of six coding exons. It has two translation start sites (see <bold>Normal gene product</bold>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="thctd" object-id="thctd.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> The only reported nonsynonymous allelic variant is c.319T&#x0003e;C (p.Ser107Pro) in exon 1; two independent studies have confirmed a lack of association between this variant and either serum thyroid hormone levels or <italic toggle="yes">SLC16A2</italic> mRNA levels [<xref ref-type="bibr" rid="thctd.REF.lagolest_n.2009.636">Lago-Lest&#x000f3;n et al 2009</xref>, <xref ref-type="bibr" rid="thctd.REF.van_der_deure.2010.1">van der Deure et al 2010</xref>]. The synonymous benign allelic variant c.1095A&#x0003e;T in exon 3 has a frequency of 3.3% in the African American population. Several synonymous variants have been recently reported but their frequencies are not known [<xref ref-type="bibr" rid="thctd.REF.frints.2008.1029">Frints et al 2008</xref>, <xref ref-type="bibr" rid="thctd.REF.visser.2013.310">Visser et al 2013</xref>].</p>
          <p><bold>Pathogenic allelic variants.</bold> More than 70 variants have been identified in <italic toggle="yes">SLC16A2</italic>. Reported variants are distributed throughout the coding region of the gene. They include full-gene and intragenic deletions and frameshift, nonsense, splice site, and missense variants. Functional studies have confirmed the pathogenesis of many of the missense variants. A particularly interesting variant, c.1834delC, results in bypassing the natural stop codon, extending the MCT8 protein by 65 amino acids and probably adding a thirteenth transmembrane domain [<xref ref-type="bibr" rid="thctd.REF.maranduba.2006.457">Maranduba et al 2006</xref>].</p>
          <table-wrap id="thctd.T.slc16a2_allelic_variants_discuss" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p><italic toggle="yes">SLC16A2</italic> Allelic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.319T&#x0003e;C<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?searchType=adhoc_search&#x00026;type=rs&#x00026;rs=rs6647476">rs6647476</ext-link>&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser107Pro</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_4" rowspan="8" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/164663748">NM_006517.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/5730045">NP_006508.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1095A&#x0003e;T<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?searchType=adhoc_search&#x00026;type=rs&#x00026;rs=rs12849161">rs12849161</ext-link>&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)&#x000a0;<sup>3</sup><break/>(p.Pro365Pro)</td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_1" rowspan="6" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.581C&#x0003e;T</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser194Phe</td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1301T&#x0003e;G</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu434Trp</td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1475T&#x0003e;C</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu492Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1501_1503del<break/>(1497_1499delCTT)</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe501del</td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1703T&#x0003e;C</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu568Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1835delC<break/>(1834delC)</td>
                  <td headers="hd_h_thctd.T.slc16a2_allelic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro612GlnfsTer68<break/>(Pro612fsTer679)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="thctd.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="thctd.TF.2.2">
                <label>2. </label>
                <p>Reference SNP</p>
              </fn>
              <fn id="thctd.TF.2.3">
                <label>3. </label>
                <p>p.(=) designates that protein has not been analyzed, but no change is expected</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">SLC16A2</italic> has two translation start sites, which generate proteins of either 613 amino acids or 539 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_006508.2">NP_006508.2</ext-link>) amino acids. Both of these MCT8 proteins contain 12 putative transmembrane domains.</p>
          <p><bold>Abnormal gene product.</bold> MCT8-specific thyroid hormone cell-membrane transporter deficiency results from a loss of function of the MCT8 protein. Most pathogenic variants cause decreased activity or complete inactivation of the MCT8 transporter [<xref ref-type="bibr" rid="thctd.REF.friesema.2006.512">Friesema et al 2006</xref>]. This leads to a decrease in thyroid hormone uptake into neurons, which is presumably the cause of the neurologic phenotype. Other as-yet unknown mechanisms cannot be excluded.</p>
        </sec>
      </sec>
      <sec id="thctd.References">
        <title>References</title>
        <sec id="thctd.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="thctd.Literature_Cited.reflist0">
            <ref id="thctd.REF.brockmann.2005.663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brockmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Best</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanefeld</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Refetoff</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene.</article-title>
                <source>J Neurol.</source>
                <volume>252</volume>
                <fpage>663</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15834651</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.ceballos.2009.2491">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ceballos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belinchon</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez-Mendoza</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grijota-Martinez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Refetoff</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morte</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernal</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Importance of Monocarboxylate transporter 8 (Mct8) for the Blood-Brain Barrier Dependent Availability of 3,5,3'-Triiodo-L-Thyronine (T3).</article-title>
                <source>Endocrinology</source>
                <volume>150</volume>
                <fpage>2491</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19147674</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.di_cosmo.2009.4450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Cosmo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>XH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Refetoff</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A thyroid hormone analogue with reduced dependence on the monocarboxylate transporter 8 (MCT8) for tissue transport.</article-title>
                <source>Endocrinology</source>
                <volume>150</volume>
                <fpage>4450</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19497976</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.dumitrescu.2004.168">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>X-H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Best</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brockmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Refetoff</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>74</volume>
                <fpage>168</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">14661163</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.dumitrescu.2009">
              <mixed-citation publication-type="book">Dumitrescu AM, Refetoff S. Cell transport defects. In: Wondisford FE, Radovick S, eds. <italic toggle="yes">Clinical Management of Thyroid Disease</italic>. Chap 22. Philadelphia, PA: Elsevier Saunders; 2009:317-23.</mixed-citation>
            </ref>
            <ref id="thctd.REF.visser.2013.310">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vrijmoeth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arts</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Toor</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <article-title>Identification, functional analysis, prevalence and treatment of monocarboxylate transporter 8 (MCT8) mutations in a cohort of adult patients with mental retardation.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2013</year>
                <volume>78</volume>
                <fpage>310</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22924588</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.friesema.2006.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friesema</surname>
                    <given-names>ECH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heuer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trajkovic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8.</article-title>
                <source>Nat Clin Pract Endocrinol Metab.</source>
                <volume>2</volume>
                <fpage>512</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">16957765</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.frints.2008.1029">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frints</surname>
                    <given-names>SGM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenzner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauters</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esch</surname>
                    <given-names>HV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>des Portes</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moog</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macville</surname>
                    <given-names>MVE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Roozendaal</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrander-Stumpel</surname>
                    <given-names>CTRM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzschach</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marynen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chelly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beldjord</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gecz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moraine</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raynaud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ropers</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Froyen</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuss</surname>
                    <given-names>AW</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>16</volume>
                <fpage>1029</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">18398436</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.fuchs.2009.240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fuchs</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfarr</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pohlenz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Elevated serum triiodothyronine and intellectual and motor disability with paroxysmal dyskinesia caused by a monocarboxylate transporter 8 gene mutation.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>51</volume>
                <fpage>240</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19018842</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.gika.2010.475">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gika</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siddiqui</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulse</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edward</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fallon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McEntagart</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jan</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Josifova</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerman-Sagie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drummond</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Refetoff</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;nnemann</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>White matter abnormalities and dystonic motor disorder associated with mutations in the SLC16A2 gene.</article-title>
                <source>Dev Med Child Neurol.</source>
                <volume>52</volume>
                <fpage>475</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19811520</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.herzovich.2007.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herzovich</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaiani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dratler</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lazzati</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tilitzky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramirez</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iorcansky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivarola</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belgorosky</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Unexpected peripheral markers of thyroid function in a patient with a novel mutation of the MCT8 thyroid hormone transporter gene.</article-title>
                <source>Horm Res.</source>
                <volume>67</volume>
                <fpage>1</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16974106</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.holden.2005.852">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holden</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zu&#x000f1;iga</surname>
                    <given-names>OF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>May</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Su</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molinero</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogers</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>X-linked MCT8 gene mutations: characterization of the pediatric neurologic phenotype.</article-title>
                <source>J Child Neurol.</source>
                <volume>20</volume>
                <fpage>852</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16417886</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.horn.2013.968">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kersseboom</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayerl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groba</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trajkovic-Arsic</surname>
                    <given-names>M</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Tetrac Can Replace Thyroid Hormone During Brain Development in Mouse Mutants Deficient in the Thyroid Hormone Transporter Mct8.</article-title>
                <source>Endocrinology.</source>
                <year>2013</year>
                <volume>154</volume>
                <fpage>968</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">23307789</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.jansen.2008.2184">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friesema</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kester</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8.</article-title>
                <source>Endocrinology.</source>
                <volume>149</volume>
                <fpage>2184</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">18187543</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.kakinuma.2005.552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kakinuma</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A novel mutation in the monocarboxylate transporter 8 gene in a boy with putamen lesions and low free T4 levels in cerebrospinal fluid.</article-title>
                <source>J Pediatr</source>
                <volume>147</volume>
                <fpage>552</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16227048</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.lagolest_n.2009.636">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lago-Lest&#x000f3;n</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iglesias</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San-Jos&#x000e9;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Areal</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eiras</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ara&#x000fa;jo-Vilar</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lado-Abeal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dom&#x000ed;nguez-Gerpe</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Prevalence and functional analysis of the S107P polymorphism (rs6647476) of the monocarboxylate transporter 8 (SLC16A2) gene in the male population of north-west Spain (Galicia).</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>70</volume>
                <fpage>636</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">18710470</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.maranduba.2006.457">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maranduba</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friesema</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kok</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kester</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serti&#x000e9;</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passos-Bueno</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Decreased cellular uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporter.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>457</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15980113</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.ramos.2011.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morandini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carre</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tron</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Floch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandelbrot</surname>
                    <given-names>L</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Pregnancy in women heterozygous for MCT8 mutations: risk of maternal hypothyroxinemia and fetal care.</article-title>
                <source>Eur J Endocrinol.</source>
                <year>2011</year>
                <volume>164</volume>
                <fpage>309</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">21098685</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.refetoff.2007.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Refetoff</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination.</article-title>
                <source>Best Pract Res Clin Endocrinol Metab</source>
                <volume>21</volume>
                <fpage>277</fpage>
                <lpage>305</lpage>
                <pub-id pub-id-type="pmid">17574009</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.roberts.2008.6251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodford</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haggerty</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tate</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grindstaff</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengesha</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raman</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerangue</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Expression of the thyroid hormone transporters MCT8 (SLC16A2) and OATP14 (SLCO1C1) at the blood-brain barrier.</article-title>
                <source>Endocrinology</source>
                <volume>149</volume>
                <fpage>6251</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">18687783</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.schwartz.2005.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>May</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogers</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bialer</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanabria</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Echeverri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubs</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voeller</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simensen</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Allan-Herndon-Dudley syndrome and the MCT8 thyroid hormone transporter.</article-title>
                <source>Am J Hum Genet</source>
                <volume>77</volume>
                <fpage>41</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">15889350</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.schwartz.2007.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome.</article-title>
                <source>Best Pract Res Clin Endocrinol Metab</source>
                <volume>21</volume>
                <fpage>307</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17574010</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.sijens.2008.1854">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sijens</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;diger</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meiners</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunsing</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>1H magnetic resonance spectroscopy in monocarboxylate transporter 8 gene deficiency.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2008</year>
                <volume>93</volume>
                <fpage>1854</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18319316</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.tonduti.2013.795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tonduti</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanderver</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berardinelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Genni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mita</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Triulzi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunstrom-Hernandez</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuffardi</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balottin</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orcesi</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>MCT8 deficiency: extrapyramidal symptoms and delayed myelination as prominent features.</article-title>
                <source>J Child Neurol.</source>
                <year>2013</year>
                <volume>28</volume>
                <fpage>795</fpage>
                <lpage>800</lpage>
                <pub-id pub-id-type="pmid">22805248</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.tsurusaki.2011.606">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsurusaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamanoue</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimbo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saitsu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyake</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Rapid detection of a mutation causing X-linked leucoencephalopathy by exome sequencing.</article-title>
                <source>J Med Genet.</source>
                <year>2011</year>
                <volume>48</volume>
                <fpage>606</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21415082</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.van_der_deure.2010.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Deure</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peeters</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Molecular aspects of thyroid hormone transporters, including MCT8, MCT10 and OATPs, and the effects of genetic variation in these transporters.</article-title>
                <source>J Mol Endocrinol.</source>
                <volume>44</volume>
                <fpage>1</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">19541799</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.vaursbarri_re.2009.114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vaurs-Barri&#x000e8;re</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deville</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarret</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Des Portes</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prats-Vinas</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Michele</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boespflug-Tanguy</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touraine</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Pelizaeus-Merzbacher-like disease presentation of MCT8 mutated male subjects.</article-title>
                <source>Ann Neurol</source>
                <volume>65</volume>
                <fpage>114</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">19194886</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.verge.2012.4515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verge</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konrad</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Cosmo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcinkowski</surname>
                    <given-names>T</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Diiodothyropropionic Acid (DITPA) in the Treatment of MCT8 Deficiency.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2012</year>
                <volume>97</volume>
                <fpage>4515</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">22993035</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.visser.2009.29">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friesema</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kester</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancilla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundgren</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunsing</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brouwer</surname>
                    <given-names>OF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel pathogenic mechanism suggested by ex vivo analysis of MCT8 (SLC16A2) mutations.</article-title>
                <source>Hum Mutat</source>
                <volume>30</volume>
                <fpage>29</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">18636565</pub-id>
              </element-citation>
            </ref>
            <ref id="thctd.REF.w_meau.2008.2084">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>W&#x000e9;meau</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pigeyre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proust-Lemoine</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Herbomez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gottrand</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ladsous</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>93</volume>
                <fpage>2084</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18334584</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="thctd.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="thctd.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Drs. Dumitrescu and Refetoff are supported in part by grants DR15070, DK07011, RR04999 and DK091016 from the National Institutes of Health. Dr. Fu is funded by an award from China Scholarship Council.</p>
        </sec>
        <sec id="thctd.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 April 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 March 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>6 July 2009 (mad) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="thctd.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Thyroid function tests from six families with MCT8<italic toggle="yes">-</italic>specific thyroid hormone cell-membrane transporter deficiency studied at the University of Chicago&#x02022; 7 affected males (M, in red squares)&#x02022; 11 carrier females (F, in green circles)&#x02022; 15 unaffected family members (N, in blue triangles)Shaded areas represent the normal range for each test. Bars are 2 SDs.* P &#x0003c;0.05** P&#x0003c;0.01*** P&#x0003c;0.001From <xref ref-type="bibr" rid="thctd.REF.dumitrescu.2009">Dumitrescu &#x00026; Refetoff [2009]</xref>. Republished with permission of Elsevier Saunders.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="thctd-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
